ALISKIREN: EVALUATION OF EFFICACY AND SAFETY OF ADMINISTRATION: PP.15.394 von Gkogkos, K., Siarkou, O., Miggos, C., Manou, M., Lampropoulou, I., Pavlidis, G.

Volltext

MS74 THE IMPACT OF EZETIMIBE ADMINISTRATION ON THE LIPID PROFILE OF PATIENTS WITH PRIMARY DYSLIPIDEMIA von Gkogkos, K., Siarkou, O., Nikitidou, O., Panara, E., Miggos, C., Plougarlis, T., Pavlidis, G.

Volltext

MS73 DECREASE OF PLASMA LEVELS OF LIPOPROTEIN A [Lp(a)] AFTER ADMINISTRATION OF L-CARNITINE von Gkogkos, K., Nikitidou, O., Panara, E., Siarkou, O., Miggos, C., Plougarlis, T., Pavlidis, G.

Volltext

P239 METABOLIC BENEFITS OF LIFESTYLE MODIFICATIONS IN PATIENTS WITH METABOLIC SYNDROME von Gkogkos, K., Miggos, C., Siarkou, O., Nikitidou, O., Panara, E., Plougarlis, T., Pavlidis, G.

Volltext

FIRST-IN-HUMAN PHASE I/II CLINICAL TRIAL OF IG-TREGS FOR GVHD PREVENTION von Lysandrou, M., Kefala, D., Christofi, P., Liga, M., Miggos, A., Papagregoriou, C., Vlachonikola, E., Savvopoulos, N., Zacharioudaki, V., Vallianou, I., Sagiadinou, E., Tsokanas, D., Theodorelou, R., Papadopoulou, A., Triantafyllou, E., Sakellari, I., Costeas, P., Chatzidimitriou, A., Yannaki, E., Spyridonidis, A.

Volltext